Connect life science data to AI due diligence that powers decisions.
Understand life science assets faster, deeper, wider, and more confidently.
Programs & affiliations
We support the licensing, M&A and investment decision makers in life science sector. The AI-powered diligence is disease area agnostic and can support evaluation of assets from public and private companies.
Biotech
01Companies and founders evaluating assets, partners, and the competitive landscape around them.
Pharma
02Business development teams evaluating in-licensing, partnerships, and acquisitions.
Life science investors
03VC, crossover, and growth funds running diligence on biotech deals at speed, with conviction.
Advisors & analysts
04Deal advisors and analysts who run diligence for clients and need insights they can trust.
Integrated across your workflow
Revonode runs underneath the workflow you already have. Deals arrive the way they always did; diligence, memo and CRM update come back the same way — done.
Firm tools
Source deal
Due diligence
IC memo
- AI workflow
- Private graph
- Public graph
- Firm-format output
Security & governance
A live report from your intelligence layer
A live slice of the workspace — ask a question, get a receipt.
Conditional
Source confidence
62
Uploaded files
Revonode report
Does the Phase 2 data support the efficacy claim in the deck?
Revonode
Partly. The deck claims a 68% responder rate; the study report gives 68% for the 100 µg arm only, n=23, with no active comparator. The pooled figure across all arms is 54%. Two of the three cited supporting papers sit behind programmes that failed in humans — down-weighted, not hidden.
Illustrative dataset — the interface is live, the deal is invented.
More capacity, and more confidence in every call
- Evidence reviewed
- 2,000+pages
- Knowledge
- 10+domains
- Learning from your archive
- 100+reports
- All workflow in one
- 1platform
One risk oversight can cost hundreds of millions
After months of diligence we licensed a rare-disease drug ready for phase III. The team missed one document, a competitor's orphan-drug designation, and lost market access to seven years of exclusivity.
Top-20 pharma director, global business development
The things investors and partners ask us most.
The model is not the product. We put a frontier AI layer above the models and in parallel to your corporate systems, with connectors to your firm's tools and 30+ APIs, agentic workflows, and a graph memory that keeps what your team has learned. It takes on the heaviest part of the work, finding the accurate source and document under your own guidelines, so your business development team decides with confidence.
AlphaSense is a broad market-intelligence search, and every subscriber sees the same content. Revonode is built for life-science diligence only. It does not only aggregate the data. It adds deep scientific analysis and market insight on top, and it learns from your own archive, so each evaluation makes the next one sharper for your firm alone.
Your data is never used to train models. Confidential files sit in an isolated data set under your licence, and your private reasoning layer is isolated by architecture. Only public knowledge is shared across reports. No co-investor, competing investor or analyst rotated off the deal can reach your documents or conclusions.
Because the frontier moves every month. Our team's experts build and maintain the leading solutions for life-science due diligence, so you do not carry that engineering weight. Your team stays on what only it can do, talking to counterparties and scaling the business, with our AI tools underneath.
It runs underneath the workflow you already have. Deals arrive the way they always did, and diligence, memo and CRM update come back the same way. We start with an introduction call or a deal you need assessed, and provide the diligence in your firm's format. Your team keeps control.
Bring us a deal.
See the diligence in hours.
Hand us a live or past data room. We'll index it, cross-check it against the external record, and show you the gaps and risks.